(HLVX)

XOMA Royalty successfully acquired 77.48% of HilleVax's outstanding shares through a tender offer at $1.95 per share plus a contingent value right, making HilleVax a wholly owned subsidiary.

HilleVax's (HLVX) short interest has risen 14.66% since its last report, with 20.02% of its shares sold short. This indicates increased bearish sentiment, as short selling is a strategy used to profit from a stock's decline.

Stifel downgraded HilleVax's stock from Buy to Hold and significantly reduced its price target from $34 to $3 after the company's Phase 2b trial for its HIL-214 vaccine failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the vaccine's development for infants.

HilleVax, Inc. (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

This down market is giving us some really intriguing stocks at cheap prices.